Radius Health, Inc. (RDUS): Price and Financial Metrics


Radius Health, Inc. (RDUS): $10.08

-0.02 (-0.20%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

RDUS Stock Price Chart Interactive Chart >

Price chart for RDUS

RDUS Price/Volume Stats

Current price $10.08 52-week high $23.00
Prev. close $10.10 52-week low $4.97
Day low $10.06 Volume 6,485,400
Day high $10.18 Avg. volume 1,172,199
50-day MA $9.44 Dividend yield N/A
200-day MA $9.46 Market Cap 480.01M

Radius Health, Inc. (RDUS) Company Bio


Radius Health is a biopharmaceutical company focused on developing new therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases including hormone responsive metastatic breast cancer. The company was founded in 2003 and is based in Waltham, Massachusetts.


RDUS Latest News Stream


Event/Time News Detail
Loading, please wait...

RDUS Latest Social Stream


Loading social stream, please wait...

View Full RDUS Social Stream

Latest RDUS News From Around the Web

Below are the latest news stories about RADIUS HEALTH INC that investors may wish to consider to help them evaluate RDUS as an investment opportunity.

Gurnet Point Capital and Patient Square Capital Complete Their Acquisition of Radius Health, Inc.

CAMBRIDGE, Mass., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Gurnet Point Capital (“Gurnet Point”) and Patient Square Capital (“Patient Square”) announced today the completion of their acquisition of Radius Health, Inc. (Nasdaq: RDUS) (“Radius”). Radius is a global, commercial-stage biopharmaceutical company focused on addressing unmet medical needs in the areas of bone health and neuro-orphan diseases. Radius’ lead product, TYMLOS® (abaloparatide) was launched in the U.S. in 2017 for the treatment of po

Yahoo | August 15, 2022

Menarini Group's Elacestrant Granted Priority Review by the U.S. FDA for Patients with ER+/HER2- Advanced or Metastatic Breast Cancer

The Menarini Group ("Menarini"), a privately held Italian pharmaceutical and diagnostics company, and Stemline Therapeutics ("Stemline"), a wholly-owned subsidiary of Menarini Group, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company's New Drug Application (NDA) for elacestrant, an investigational selective estrogen receptor degrader (SERD), for patients with ER+/HER2- advanced or metastatic breast cancer. The FDA has granted the application Priority Review

Yahoo | August 11, 2022

Mass. M&A activity picks up among life sciences firms

Mergers and acquisitions are starting to ramp up in Massachusetts' life sciences sector, but analysts believe the biggest buys are still yet to come.

Yahoo | July 28, 2022

Dave & Busters Entertainment and USA Truck Stock See Action From Activist Investors

Hill Path Capital disclosed a large stake in dining-and-entertainment firm Dave & Buster’s, and Magnetar Capital reported a 6% stake in logistics firm USA Truck.

Yahoo | July 15, 2022

Velan-Repertoire to Withdraw Director Nominations Due to Pending Sale of Radius Health

ALPHARETTA, Ga., July 11, 2022--Velan Capital Investment Management LP and Repertoire Partners LP (together with the other participants in their solicitation, "Velan-Repertoire" or "we"), collectively one of the largest stockholders of Radius Health, Inc. ("Radius" or the "Company") (NASDAQ: RDUS), with beneficial ownership of approximately 7.7% of the outstanding shares and economic exposure to approximately 10.1% of the outstanding shares, today released the following statement:

Yahoo | July 11, 2022

Read More 'RDUS' Stories Here

RDUS Price Returns

1-mo N/A
3-mo N/A
6-mo 57.01%
1-year -38.54%
3-year -55.00%
5-year -64.39%
YTD 45.66%
2021 -61.25%
2020 -11.41%
2019 22.26%
2018 -48.10%
2017 -16.46%

Continue Researching RDUS

Want to see what other sources are saying about Radius Health Inc's financials and stock price? Try the links below:

Radius Health Inc (RDUS) Stock Price | Nasdaq
Radius Health Inc (RDUS) Stock Quote, History and News - Yahoo Finance
Radius Health Inc (RDUS) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7751 seconds.